Will Gain Therapeutics stock go up?

According to Danelfin AI, Gain Therapeutics has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.27%) is -2.55% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Gain Therapeutics stock?

The Gain Therapeutics target price is $8.27 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Gain Therapeutics stock right now?

Gain Therapeutics has today a Hold rating (AI Score 4/10), according to Danelfin AI. Its probability of beating the market in 3 months (48.27%) is -2.55% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Gain Therapeutics stock is a good buy .

Is Gain Therapeutics undervalued right now?

Based on analysts, the average price target upside for Gain Therapeutics is +311.43% (1Y). According to Danelfin AI, Gain Therapeutics has today an AI Score of 4/10 (Hold Rating).

What was the price range of Gain Therapeutics stock over the past 12 months?

The Gain Therapeutics stock price range over the past 12 months has been $1.44 - $4.18.

What is going on with Gain Therapeutics stock in the last 3 months?

The Gain Therapeutics stock performance in the last quarter has been +3.60%.

Does Gain Therapeutics offer dividend payments?

No, Gain Therapeutics does not currently pay dividends.

What is the current market capitalization of Gain Therapeutics?

Gain Therapeutics's market cap is $84.88M, as of 2026-07-02 08:00.

When is the next GANX earnings report date?

GANX will publish its next earnings report on 2026-05-11.

Gain Therapeutics Inc (GANX) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

GANX AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+0.34%
Direction and strength of recent price movements
Earnings Quality+0.29%
Stability and reliability of reported earnings
Size & Liquidity+0.28%
Company size and trading liquidity
Volatility+0.27%
How much the stock price tends to fluctuate
Valuation+0.03%
How the stock is priced relative to its fundamentals

Sentiment-2.50%
How analysts and the market view the stock
Financial Strength-1.26%
Balance sheet strength and financial resilience

GANX probability advantage of beating the market (3M):

-2.55%

Technical

Gain Therapeutics (GANX) has a Technical Score of 7/10 because, according to only technical analysis, it has a probability advantage of +3.24% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.64%) and the probability of GANX (53.88%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.64%
GANX probability advantage of beating the market (only technical, 3M)+3.24%
GANX probability of beating the market (3M)53.88%

GANX probability advantage of beating the market (only technical, 3M): +3.24%

The AI-powered technical analysis of Gain Therapeutics (GANX) is only based on the 28 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of GANX:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	-1.44%
Technical	Upgrade to Pro to unlock	+1.35%
Technical	Upgrade to Pro to unlock	+0.78%
Technical	Upgrade to Pro to unlock	+0.76%
Technical	Upgrade to Pro to unlock	-0.59%
Technical	Upgrade to Pro to unlock	+0.45%
Technical	Upgrade to Pro to unlock	-0.44%
Technical	Upgrade to Pro to unlock	+0.37%
Technical	Upgrade to Pro to unlock	-0.35%
Technical	Upgrade to Pro to unlock	+0.33%
Technical	Upgrade to Pro to unlock	-0.33%
Technical	Upgrade to Pro to unlock	+0.28%
Technical	Upgrade to Pro to unlock	+0.25%
Technical	Upgrade to Pro to unlock	-0.24%
Technical	Upgrade to Pro to unlock	+0.23%

Rest of Alpha Signals: +0.73%

GANX probability advantage of beating the market (only technical, 3M)Total:+3.24%
GANX Technical Score

Significant changes Vs previous day

GANX Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.01
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

GANX Proven Hold Signal & Price Forecast

This is the price chart for GANX from January 2, 2026 until today. The chart indicates, in yellow, the 28 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

GANX Average Past Performance & Win Rate

Three months after its 615 Hold signals since July 2026, GANX had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

615 Past GANX Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-31.01%
Average Alpha				-42.50%
Win Rate (% Positive Perf.)				18.06%
% Positive Alpha				11.45%

GANX Frequently Asked Questions

Will Gain Therapeutics stock go up?
According to Danelfin AI, Gain Therapeutics has today an AI Score of 4/10 (Hold rating), because its probability of beating the market in 3 months (48.27%) is -2.55% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Gain Therapeutics stock?
Is it a good time to buy, sell, or hold Gain Therapeutics stock right now?
Is Gain Therapeutics undervalued right now?
What was the price range of Gain Therapeutics stock over the past 12 months?
What is going on with Gain Therapeutics stock in the last 3 months?
Does Gain Therapeutics offer dividend payments?
What is the current market capitalization of Gain Therapeutics?
When is the next GANX earnings report date?

Gain Therapeutics Inc Company Profile

Headquartered in Bethesda, Maryland, Gain Therapeutics, Inc. operates as a clinical-stage biotechnology entity involved in the discovery and strategic development of allosteric therapies. Its forerunner drug candidate, GT-02287 devised for tackling GBA1 Parkinson's disease is currently under rigorous assessment in a Phase 1 clinical trial.

The company utilizes its innovative drug discovery platform - Magellan. This resourceful platform harnesses the power to discover unique allosteric binding sites on proteins implicated in diseases, capitalizing on unexplored opportunities by locating pockets that evade detection or drugging with existing technologies.

Enhanced with cutting-edge AI technology and machine learning tools, Magellan also integrates virtual screening capabilities to explore the proliferating on-demand compound libraries comprising chemical spaces of nearly 50 billion compounds.

With its groundbreaking platform at play, Gain Therapeutics escalates the process of drug discovery stressing on unlocking pioneering treatments capable of modifying diseases. The primary focus lies on addressing challenging disorders that have been notoriously difficult to treat or considered incurable such as neurodegenerative diseases, rare genetic disorders along with oncology.

Venturing into this scientific endeavor makes them a promising entity within their sphere. Originally established in 2017, Gain Therapeutics has marked its place as an emerging name within the extensive landscape of biotech companies striving towards medical advancements.

Sector:
Country:United States
Industry:
Address:4800 Montgomery Lane, Suite 220, Bethesda
Employees:20
Website:gaintherapeutics.com

Pros

Proprietary computational drug discovery platform technology

Focus on unmet-need rare and CNS diseases

Platform scalability across multiple therapeutic targets

Potential for strategic partnerships and licensing deals

High patient switching costs for effective rare disease therapies

Cons

High capital intensity of drug development

Protracted and uncertain drug development timelines

Regulatory approval risk for novel therapies

Reliance on early-stage pipeline with no commercial products

Competition from larger pharmaceutical companies and other biotechs

GANX Stock AI Analysis